BACKGROUND: Ductal carcinoma in situ (DCIS) of the breast is a precursor of invasive breast carcinoma. DNA methylation alterations are thought to be an early event in progression of cancer, and may prove valuable as a tool in clinical decision making and for understanding neoplastic development. RESULTS: We generate genome-wide DNA methylation profiles of 285 breast tissue samples representing progression of cancer, and validate methylation changes between normal and DCIS in an independent dataset of 15 normal and 40 DCIS samples. We also validate a prognostic signature on 583 breast cancer samples from The Cancer Genome Atlas. Our analysis reveals that DNA methylation profiles of DCIS are radically altered compared to normal breast tissue, involving more than 5,000 genes. Changes between DCIS and invasive breast carcinoma involve around 1,000 genes. In tumors, DNA methylation is associated with gene expression of almost 3,000 genes, including both negative and positive correlations. A prognostic signature based on methylation level of 18 CpGs is associated with survival of breast cancer patients with invasive tumors, as well as with survival of patients with DCIS and mixed lesions of DCIS and invasive breast carcinoma. CONCLUSIONS: This work demonstrates that changes in the epigenome occur early in the neoplastic progression, provides evidence for the possible utilization of DNA methylation-based markers of progression in the clinic, and highlights the importance of epigenetic changes in carcinogenesis.
BACKGROUND:Ductal carcinoma in situ (DCIS) of the breast is a precursor of invasive breast carcinoma. DNA methylation alterations are thought to be an early event in progression of cancer, and may prove valuable as a tool in clinical decision making and for understanding neoplastic development. RESULTS: We generate genome-wide DNA methylation profiles of 285 breast tissue samples representing progression of cancer, and validate methylation changes between normal and DCIS in an independent dataset of 15 normal and 40 DCIS samples. We also validate a prognostic signature on 583 breast cancer samples from The Cancer Genome Atlas. Our analysis reveals that DNA methylation profiles of DCIS are radically altered compared to normal breast tissue, involving more than 5,000 genes. Changes between DCIS and invasive breast carcinoma involve around 1,000 genes. In tumors, DNA methylation is associated with gene expression of almost 3,000 genes, including both negative and positive correlations. A prognostic signature based on methylation level of 18 CpGs is associated with survival of breast cancerpatients with invasive tumors, as well as with survival of patients with DCIS and mixed lesions of DCIS and invasive breast carcinoma. CONCLUSIONS: This work demonstrates that changes in the epigenome occur early in the neoplastic progression, provides evidence for the possible utilization of DNA methylation-based markers of progression in the clinic, and highlights the importance of epigenetic changes in carcinogenesis.
Authors: Kristen N Stevens; Sara Lindstrom; Christopher G Scott; Deborah Thompson; Thomas A Sellers; Xianshu Wang; Alice Wang; Elizabeth Atkinson; David N Rider; Jeanette E Eckel-Passow; Jajini S Varghese; Tina Audley; Judith Brown; Jean Leyland; Robert N Luben; Ruth M L Warren; Ruth J F Loos; Nicholas J Wareham; Jingmei Li; Per Hall; Jianjun Liu; Louise Eriksson; Kamila Czene; Janet E Olson; V Shane Pankratz; Zachary Fredericksen; Robert B Diasio; Adam M Lee; John A Heit; Mariza DeAndrade; Ellen L Goode; Robert A Vierkant; Julie M Cunningham; Sebastian M Armasu; Richard Weinshilboum; Brooke L Fridley; Anthony Batzler; James N Ingle; Norman F Boyd; Andrew D Paterson; Johanna Rommens; Lisa J Martin; John L Hopper; Melissa C Southey; Jennifer Stone; Carmel Apicella; Peter Kraft; Susan E Hankinson; Aditi Hazra; David J Hunter; Douglas F Easton; Fergus J Couch; Rulla M Tamimi; Celine M Vachon Journal: Hum Mol Genet Date: 2012-04-24 Impact factor: 6.150
Authors: Aslaug Aa Muggerud; Jo Anders Rønneberg; Fredrik Wärnberg; Johan Botling; Florence Busato; Jovana Jovanovic; Hiroko Solvang; Ida Bukholm; Anne-Lise Børresen-Dale; Vessela N Kristensen; Therese Sørlie; Jörg Tost Journal: Breast Cancer Res Date: 2010-01-07 Impact factor: 6.466
Authors: Youdinghuan Chen; Jonathan D Marotti; Erik G Jenson; Tracy L Onega; Kevin C Johnson; Brock C Christensen Journal: Exp Mol Pathol Date: 2017-07-12 Impact factor: 3.362
Authors: Helga Bergholtz; Tonje G Lien; David M Swanson; Arnoldo Frigessi; Maria Grazia Daidone; Jörg Tost; Fredrik Wärnberg; Therese Sørlie Journal: NPJ Breast Cancer Date: 2020-06-17
Authors: Vijay Kumar Eedunuri; Kimal Rajapakshe; Warren Fiskus; Chuandong Geng; Sue Anne Chew; Christopher Foley; Shrijal S Shah; John Shou; Junaith S Mohamed; Cristian Coarfa; Bert W O'Malley; Nicholas Mitsiades Journal: Mol Endocrinol Date: 2015-06-12
Authors: Wenbing Xie; Ioannis Kagiampakis; Lixia Pan; Yang W Zhang; Lauren Murphy; Yong Tao; Xiangqian Kong; Byunghak Kang; Limin Xia; Filipe L F Carvalho; Subhojit Sen; Ray-Whay Chiu Yen; Cynthia A Zahnow; Nita Ahuja; Stephen B Baylin; Hariharan Easwaran Journal: Cancer Cell Date: 2018-02-12 Impact factor: 31.743
Authors: Jacob K Kresovich; Peter H Gann; Serap Erdal; Hua Y Chen; Maria Argos; Garth H Rauscher Journal: Epigenomics Date: 2018-03-12 Impact factor: 4.778
Authors: Wei Sun; Paul Bunn; Chong Jin; Paul Little; Vasyl Zhabotynsky; Charles M Perou; David Neil Hayes; Mengjie Chen; Dan-Yu Lin Journal: Nucleic Acids Res Date: 2018-04-06 Impact factor: 16.971
Authors: Brian Z Huang; Alexandra M Binder; Catherine A Sugar; Chun R Chao; Veronica Wendy Setiawan; Zuo-Feng Zhang Journal: Epigenomics Date: 2020-09-01 Impact factor: 4.778